



P. 1/2

510(k) Summary

Preparation Date: September 29, 2006

OCT 31 2006

Applicant/Sponsor: Biomet Manufacturing Corp.
56 East Bell Drive
Warsaw, Indiana 46582

Contact Person: Gary Baker M.S. RAC
Regulatory Specialist
Biomet Manufacturing Corp.
Tel: (574) 267-6639 Extension 1568
Fax: (574) 372-1683
e-mail: gary.baker@biometmail.com

Proprietary Name: Altra™ Press-Fit Hip System

Common Name: Hip Stem

Classification Code(s)/Name(s):

LZO – Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis §888.3353.

KWA – Hip joint metal/metal semi-constrained, with an uncemented acetabular component, prosthesis §888.3330

KWZ – Hip joint metal/polymer constrained cemented or uncemented prosthesis §888.3310

JDL – Hip joint metal/metal semi-constrained, with a cemented acetabular component, prosthesis §888.3320

JDI – Hip joint metal/polymer semi-constrained cemented prosthesis §888.3350

MAY – Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis §888.3353.

MEH – Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis §888.3353.

LPH – Hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis §888.3358

KWL – Hip joint femoral (hemi-hip) metallic cemented or uncemented prosthesis §888.3360.

LWJ – Hip joint femoral (hemi-hip) metallic cemented or uncemented prosthesis §888.3360.

KWY – Hip joint femoral (hemi-hip) metal/polymer cemented or uncemented prosthesis §888.3390

MAILING ADDRESS
P.O. Box 587
Warsaw, IN 46581-0587

SHIPPING ADDRESS
56 E. Bell Drive
Warsaw, IN 46582

OFFICE
574.267.6639

FAX
574.267.8187

E-MAIL
biomet@biomet.com

Legally Marketed Devices To Which Substantial Equivalence Is Claimed:

Fine Grain Cast Cobalt Chromium Hip Stem – K953925

Device Description:

The Altra™ Press-Fit Hip System consists of a hip stem made from Ti-6Al-4V titanium alloy conforming to ASTM F-136.

Intended Use:

Indications for Use:

1. Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis.
2. Rheumatoid arthritis.
3. Correction of functional deformity.
4. Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable using other techniques.
5. Revision of previously failed total hip arthroplasty.

The Altra™ Press-Fit Hip System is intended for uncemented use only.

Summary of Technologies:

The Altra™ Press-Fit Hip System incorporates a similar design with similar technological features as the predicate hip stem. It has the same intended use, indications for use, and utilizes the same Biomet Type I Taper as the predicate stems. These similarities demonstrate that the Altra™ Press-Fit Hip System is substantially equivalent to the predicate hip stem.

Non-Clinical Testing:

Mechanical testing demonstrated that the Altra™ Press-Fit Hip System is substantially equivalent to the predicate device.

Clinical Testing:

Clinical testing was not conducted in support of substantial equivalence.

All trademarks are property of Biomet, Inc.



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

OCT 31 2006

Biomet Manufacturing Corp.
% Mr. Gary Baker, M.S., RAC
56 East Bell Drive
Warsaw, Indiana 46582

Re: K063002

Trade/Device Name: Altra Press-Fit Hip Stem
Regulation Number: 21 CFR 888.3330
Regulation Name: Hip joint metal/metal semi-constrained, with an uncemented acetabular component, prosthesis
Regulatory Class: Class III
Product Codes: KWA, JDL, LZO, KWZ, JDI, MAY, MEH, LPH, KWL, LWJ, KKY
Dated: September 29, 2006
Received: October 2, 2006

Dear Mr. Baker:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Mark N. Melkerson", written over a horizontal line.

Mark N. Melkerson

Director

Division of General, Restorative
and Neurological Devices

Office of Device Evaluation

Center for Devices and
Radiological Health

Enclosure

K063002

Indications for Use

510(k) Number (if known): _____

Device Name: Altra™ Press-Fit Hip System

Indications For Use:

1. Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis
2. Rheumatoid arthritis
3. Correction of functional deformity
4. Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable using other techniques
5. Revision of previously failed total hip arthroplasty.

The Altra™ Press-Fit Hip System is intended for uncemented use only.

Prescription Use YES
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use NO
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)


(Division Sign-Off)

**Division of General, Restorative,
and Neurological Devices**

Page 1 of 1

510(k) Number K063002